NCT05029466 - Psilocybin for Treatment-Resistant Depression
Clinical Trial in Mississauga, Ontario
Completed
The purpose of this study is to see if psilocybin, an investigational drug, is safe and well tolerated. Researchers also want to know if psilocybin can improve symptoms of depression. This study will see if psilocybin is safe and well tolerated by tracking changes in suicidal thoughts and behaviour, monitoring if any participants choose to stop participating in the study, and measuring any serious side effects, as... Source record lists lead sponsor Brain and Cognition Discovery Foundation and overall status Completed.
Last verified: 2026-06-12
NCT06072898 - A Randomized Neuroimaging Trial of Psilocybin in Depression
Clinical Trial in Toronto, Ontario
Recruiting
The goal of this neuroimaging clinical trial is to test whether psilocybin produces significant immediate changes in functional brain activity in networks associated with mood regulation and depression compared to placebo in patients with depression. The trial aims to determine if psilocybin: 1. Changes connectivity within brain networks associated with mood and depression 2. Changes blood flow in brain regions as... Source record lists lead sponsor Sunnybrook Health Sciences Centre and overall status Recruiting.
Last verified: 2026-06-12
NCT06299319 - Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD
Clinical Trial in Toronto, Ontario
Enrolling By Invitation
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. There is interest to see if similar effects may be provided in those with obsessive compulsive disorder (OCD). The purpose of this study is to evaluate the safety, feasibility, and clinical effects of psilocybin administra... Source record lists lead sponsor Centre for Addiction and Mental Health and overall status Enrolling By Invitation.
Last verified: 2026-06-12
NCT06341426 - Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin
Clinical Trial in Toronto, Ontario
Recruiting
The purpose of this study is to see if one or two doses of psilocybin is more effective in relieving depressive symptoms in patients with treatment-resistant depression (TRD). Researchers also want to know if a second dose of psilocybin is safe and well-tolerated. This study will see if psilocybin is effective, safe, and well-tolerated by tracking changes in depressive symptoms, suicidality, and side effects. This... Source record lists lead sponsor University Health Network, Toronto and overall status Recruiting.
Last verified: 2026-06-12
NCT07063862 - Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)
Clinical Trial in Brampton, Ontario
Recruiting
About 30-50% of patients with advanced illness experience depression, anxiety, or decreased sense of purpose and autonomy. Together, these are called psychological distress. Treatment options such as medication and therapy are available; however, they do not always work and can be time-consuming and expensive. We need treatments that work well, quickly, and can be available to all patients with advanced illness wh... Source record lists lead sponsor Bruyère Health Research Institute. and overall status Recruiting.
Last verified: 2026-06-12
